scholarly journals The Effect of Korean Red Ginseng on Sexual Function in Premenopausal Women: Placebo-Controlled, Double-Blind, Crossover Clinical Trial

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Ho Seok Chung ◽  
Insang Hwang ◽  
Kyung Jin Oh ◽  
Mi Na Lee ◽  
Kwangsung Park

This study investigated whether Korean red ginseng (KRG) extracts could improve sexual function in premenopausal women. Forty-one premenopausal women participated in this placebo-controlled, double-blind, and crossover clinical study with administration of either three ginseng capsules (1 g per capsule) or placebo daily. After 8 weeks of medication of KRG or placebo, medication was changed for the subjects to placebo or KRG after 2 weeks of washout period. The efficacy of KRG extracts was measured by using Female Sexual Function Index (FSFI).Results. Twenty-three women completed the study. Total FSFI scores increased after KRG treatment (from20.13±2.87to23.98±4.10,p=0.015) and placebo treatment (from20.06±2.64to23.78±3.28,p=0.003). However, this change was not significantly different between the two groups (p=0.702). KRG treatment significantly improved sexual desire, arousal, orgasm, and satisfaction domains; however, there was no treatment effect compared with placebo. There was a case of gastric discomfort after taking KRG extracts. Oral administration of KRG extracts improved sexual function in premenopausal women; however, there were no statistical significant changes compared to placebo. It implies that KRG extracts have a substantial placebo effect in premenopausal women with sexual dysfunction.

2019 ◽  
Vol 43 (4) ◽  
pp. 676-683 ◽  
Author(s):  
Li Zhang ◽  
Xiaoyun Chen ◽  
Yanqi Cheng ◽  
Qilong Chen ◽  
Hongsheng Tan ◽  
...  

2010 ◽  
Vol 7 (4) ◽  
pp. 1469-1477 ◽  
Author(s):  
Kyung-Jin Oh ◽  
Myeong-Jeong Chae ◽  
Hyun-Suk Lee ◽  
Hee-Do Hong ◽  
Kwangsung Park

2016 ◽  
Vol 10 (7-8) ◽  
pp. 251 ◽  
Author(s):  
Eyup Burak Sancak ◽  
Sevilay Oguz ◽  
Tugba Akbulut ◽  
Aysegul Uludag ◽  
Alpaslan Akbas ◽  
...  

<p><strong>Introduction:</strong> We sought to evaluate the association of female sexual dysfunction (FSD) with adrogenetic alopecia (AGA) and metabolic syndrome (MetS) in premenopausal women.</p><p><strong>Methods:</strong> From December 2013 to June 2015, we performed a case-control, prospective study of 115 patients with AGA and 97 age-matched control patients without AGA from among premenopausal<br />women who visited dermatology clinics of the two reference hospitals. Comprehensive history, anthropometric measurements, and questionnaire administration were performed for each of the total of 212 women. The Female Sexual Function Index (FSFI) was used to assess the key dimensions of female sexual function. AGA was assessed and graded by an experienced dermatologist according to Ludwig’s classification. The MetS assessment was made according to the NCEP-ATP III criteria.</p><p><strong>Results:</strong> In univariate analysis, age, weight, waist circumference, hip circumference, waist-to-hip ratio, body mass index (BMI), AGA, MetS, cardiovascular event, marital status, hypertension, high fasting plasma glucose, high triglyceride, large waist, total testosterone, and free testosterone were associated with presence of FSD. In logistic regression analysis, age (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.13‒1.30; p&lt;0.001), AGA (OR 3.42, 95% CI 1.31‒8.94; p=0.017), MetS (OR 5.39, 95% CI 1.34‒21.62; p=0.012), and free testosterone (OR 0.18, 95% CI 0.09‒0.37; p&lt;0.001) were independently associated with FSD.</p><p><strong>Conclusions:</strong> Our study suggests that age, AGA, MetS, and free testosterone may have strong impact on sexual function in premenopausal women. Further studies with population-based and longitudinal design should be conducted to confirm this finding.</p>


Sign in / Sign up

Export Citation Format

Share Document